Page last updated: 2024-08-22

zirconium and dasatinib

zirconium has been researched along with dasatinib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Aragon-Sanabria, V; Bradbury, MS; Brennan, CW; Carlin, S; Chen, F; Chen, PM; Gonen, M; Huse, J; Juthani, R; Longo, VA; Ma, K; Madajewski, B; Overholtzer, M; Rudin, CM; Turker, MZ; Wiesner, U; Yoo, B; Zanzonico, P; Zhang, L1
Boerner, JL; Kim, S; McKnight, BN; Viola, NT1

Other Studies

2 other study(ies) available for zirconium and dasatinib

ArticleYear
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-01, Volume: 26, Issue:1

    Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Drug Delivery Systems; Glioblastoma; Iodine Radioisotopes; Mice; Nanoparticles; Neoplasm Grading; Oligopeptides; Positron-Emission Tomography; Protein Kinase Inhibitors; Radioisotopes; Silicon Dioxide; Zirconium

2020
Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    Breast cancer research : BCR, 2020, 04-15, Volume: 22, Issue:1

    Topics: Animals; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Mice; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Radioisotopes; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays; Zirconium

2020